Cambridge Investment Research Advisors
VTGN icon

Cambridge Investment Research Advisors’s VistaGen Therapeutics VTGN Stock Holding History

Cambridge Investment Research Advisors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-852
Closed -$3K – 3301
2023
Q1 		$3K Sell
852
-39
-4% -$205 ﹤0.01% 3145
2022
Q4 		$3K Buy
891
+540
+154% +$2.03K ﹤0.01% 3093
2022
Q3 		$2K Buy
+351
New +$3.48K ﹤0.01% 3047

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cambridge Investment Research Advisors's VTGN Position: Q2 2023 in Review

Cambridge Investment Research Advisors sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 852 shares — an estimated $3K sold.

Cambridge Investment Research Advisors first reported a position in VTGN in Q3 2022 and held it in 3 quarters. The position peaked at $3K in Q1 2023. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • Cambridge Investment Research Advisors reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 852 VistaGen Therapeutics shares in Q2 2023, an estimated $3K.
  • Cambridge Investment Research Advisors first reported a position in VistaGen Therapeutics in Q3 2022 and held it in 3 quarters.
  • Cambridge Investment Research Advisors's VistaGen Therapeutics position peaked at $3K in Q1 2023.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on Cambridge Investment Research Advisors's 13F filing for Q2 2023, filed 13 Jul 2023.